Severe Acute Respiratory News and Research

RSS

Nucleocapsid protein preferentially binds to structured and longer RNA to deliver viral proteins in host circulation

Results from a new study could be crucial in studying the molecular and biochemical basis of SARS-CoV-2 infection at a more granular level and help in strategizing therapeutic solutions to treat and manage COVID-19 effectively.

5 Jan 2022

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

A new preprint research paper posted to the medRxiv* server reports the induction of high neutralizing activity in these patients against the Omicron VOC with a booster dose.

5 Jan 2022

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

An interesting preprint research paper describes structural changes resulting from the multiple mutations found in the recent Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. In addition, the research describes the consequent effects of these changes on Omicron’s infectivity and immune evasion capabilities.

5 Jan 2022

Transplant recipients benefit from a COVID-19 vaccine booster

A new preprint research paper posted to the medRxiv* server describes the reduction in humoral immunity in SOTR following vaccination, as well as the improvement with an additional dose of the vaccine.

4 Jan 2022

Time since COVID vaccination is a key driver of breakthrough Omicron infections

Published on the preprint medRxiv* server and awaiting peer review, the findings showed that the significant factor behind breakthrough Omicron infections is the timing from vaccination. The time between vaccination and breakthrough infections induced effective or cross-reactive neutralizing antibodies that neutralize Omicron after Alpha or Delta breakthrough infections.

4 Jan 2022

New study on NAbs against SARS-CoV-2 Omicron variant after vaccination or infection

A recent study suggests neutralizing antibody responses against variants of concern, including Omicron, differs significantly between vaccinated and naturally infected individuals. The research, posted to the medRxiv* preprint server, focused on vaccinated individuals who are pregnant — an understudied group in COVID-19 research.

4 Jan 2022

Novel insight into the immune characteristics of bats

Many studies have indicated that bats are significant reservoirs of innumerable viruses, such as influenza, coronaviruses, and rabies. These studies have also reported that bats predominantly remain asymptomatic or develop mild diseases during viral infections caused by henipaviruses, Ebola virus, coronaviruses, etc.

4 Jan 2022

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

A new study, published on the medRxiv* preprint server, investigated the changes in SARS-CoV-2 antibody levels among HCWs after SARS-CoV-2 vaccination. The study also assessed whether low responders produced sufficient SARS-CoV-2 anti-spike and neutralizing antibodies.

4 Jan 2022

Both symptomatic and asymptomatic COVID-19 associated with increased risk of cardiovascular events

Researcers determine the risk of symptomatic and asymptomatic SARS-CoV-2 infection on post-acute cardiovascular events and all-cause mortality.

4 Jan 2022

Experts cautiously optimistic about risks of Delta-Omicron mutations mix

Researchers evaluate the risk of the P681R, N501Y, and D614G mutations of current interest co-occurring naturally due to convergent evolution.

4 Jan 2022

SARS-CoV-2 mRNA vaccine boosters crucial in maintaining neutralizing antibodies in HCPs

Researchers evaluate the effects of a third dose of the BNT162b2 mRNA vaccine on antibody titers and breakthrough infections in healthcare workers.

4 Jan 2022

Israeli study confirms drop in BNT162b2 efficacy after six months

Researchers determine whether BNT162b2 vaccination has become less efficient in preventing infection over time.

4 Jan 2022

A closer look at the relationship between COVID-19 and Alzheimer’s disease

Researchers discuss the findings of previous studies on the role of SARS-CoV-2 infection in the progression of Alzheimer's Disease.

4 Jan 2022

Efficacy of antibodies induced by natural infection, vaccination, or both against SARS-CoV-2 Omicron and Beta variants

A study has demonstrated that antibodies induced by two-dose COVID-19 vaccination or natural infection exhibit very low neutralizing activity against the omicron variant of SARS-CoV-2.

4 Jan 2022

Study suggests increased vaccine breakthrough for SARS-CoV-2 Omicron variant in Houston, Texas

A recent study reveals early signals of substantially increased vaccine breakthrough for the Omicron variant of SARS-CoV-2 in Houston, Texas.

4 Jan 2022

Characteristics and outcomes in patients hospitalized with COVID-19 in South Africa

A new research letter assessed patients hospitalized with a positive SARS-CoV-2 test during the fourth wave compared to the previous waves.

4 Jan 2022

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

An independent study confirms that current and prospective antiviral treatments are effective in inhibiting severe infection from SARS-CoV-2.

4 Jan 2022

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

A new study found that applying pan-sarbecovirus nanobodies shows a strong affinity toward all sarbecovirus clades and neutralized SARS-CoV-2 receptor binding domains

4 Jan 2022

SARS-CoV-2 spike T cell responses from vaccines or infection remain robust against Omicron

In a new study, a team of researchers from multi-national institutions discovered that 70-80% of CD4 and CD8 T cell responses to spike were consistent across research groups. Moreover, although having far more mutations, the magnitude of Omicron cross-reactive T cells was comparable to that of the Beta and Delta variants.

3 Jan 2022

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

The advent of the B.1.1.529 (Omicron) severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) variant, detected initially in Botswana and South Africa and now found in over 135 countries as of January 3, 2022, has sparked fears of a new global wave of infections and hospitalizations

3 Jan 2022

Severe Acute Respiratory News and Research

Nucleocapsid protein preferentially binds to structured and longer RNA to deliver viral proteins in host circulation

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

Transplant recipients benefit from a COVID-19 vaccine booster

Time since COVID vaccination is a key driver of breakthrough Omicron infections

New study on NAbs against SARS-CoV-2 Omicron variant after vaccination or infection

Novel insight into the immune characteristics of bats

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

Both symptomatic and asymptomatic COVID-19 associated with increased risk of cardiovascular events

Experts cautiously optimistic about risks of Delta-Omicron mutations mix

SARS-CoV-2 mRNA vaccine boosters crucial in maintaining neutralizing antibodies in HCPs

Israeli study confirms drop in BNT162b2 efficacy after six months

A closer look at the relationship between COVID-19 and Alzheimer’s disease

Efficacy of antibodies induced by natural infection, vaccination, or both against SARS-CoV-2 Omicron and Beta variants

Study suggests increased vaccine breakthrough for SARS-CoV-2 Omicron variant in Houston, Texas

Characteristics and outcomes in patients hospitalized with COVID-19 in South Africa

In vitro effect of several antiviral drugs against various SARS-CoV-2 variants of concern

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

SARS-CoV-2 spike T cell responses from vaccines or infection remain robust against Omicron

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News